Why Pelthos Therapeutics Inc.’s (PTHS) Stock Is Up 6.56%
As of Monday, August 24, Pelthos Therapeutics Inc.’s PTHS share price has surged by 6.56%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Commentary & Analysis
Why Pelthos Therapeutics Inc.’s (PTHS) Stock Is Up 5.75%
As of Tuesday, August 18, Pelthos Therapeutics Inc.’s PTHS share price has surged by 5.75%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Pelthos Therapeutics Inc.’s (PTHS) Stock Is Up 6.02%
As of Tuesday, August 18, Pelthos Therapeutics Inc.’s PTHS share price has surged by 6.02%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Pelthos Therapeutics Inc.’s (PTHS) Stock Is Down 9.27%
As of Thursday, August 13, Pelthos Therapeutics Inc.’s PTHS share price has dipped by 9.27%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Pelthos Therapeutics Inc.’s (PTHS) Stock Is Down 5.62%
As of Monday, August 03, Pelthos Therapeutics Inc.’s PTHS share price has dipped by 5.62%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | PTHS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $95.8 | $288.9 | 21% |
|
| Shares Out (Mil) | 3.5 | 54.0 | 11% |
|
| Institutional Ownership | 76.5% | 93.1% | 46% |
|
| Float (Mil) | 1.4 | 41.4 | 4% |
|
| Beta | 3.13 | 0.94 | 98% |
|
| Avg Daily Volume (000s) | 59 | 480 | 30% |
|
| Price Change (52-week) |
8.9% | 59.9% | 54% |
|
| Growth | PTHS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 142.6% | 14.1% | 99% |
|
| Net Income (5yr) | (128.2%) | (10.1%) | 1% |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($3.340) | ($18.820) | ($5.683) | |
| Month Ago EPS | ($1.893) | ($10.663) | ($2.125) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($1.893) | ($10.663) | ($2.125) | |
| Year/Year Chg | (49.5%) | (18.3%) | (103.3%) | |
| Financials | PTHS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $43 | $37 | 19% |
|
| Net Income (TTM) (Mil) | ($86) | ($43) | 12% |
|
| EPS (TTM) | ($26.360) | ($1.500) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($42) | ($31) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $25 | $2 | 64% |
|
| Long-Term Debt (Q1) (Mil) | $73 | $4 | 42% |
|
| Enterprise Value (Q1) (Mil) | $151 | $190 | 24% |
|
| Valuation | PTHS | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PTHS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 75.6% | 66.9% | 86% |
|
| Net Margin | (199.5%) | (74.2%) | 5% |
|
| ROA | (125.0%) | (47.7%) | 4% |
|
| ROE | na | (55.0%) | na |
|
| Liabilities to Assets | 101.1% | 29.6% | 94% |
|
| F-Score | 3 | 3 | 18% |
|
Pelthos Therapeutics Inc. did not pass any screens on 9/2/2026.
